Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betibeglogene-autotemcel (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NorthStar
  • Sponsors bluebird bio

    • Most Recent Events

    • 12 Dec 2023 Results of an analysis reporting iron management outcomes in patients who completed either a phase 1/2 (NCT01745120, NCT02151526) or phase 3 beti-cel parent studies (NCT02906202 and NCT03207009) and subsequently enrolled in the long-term follow-up study (NCT02633943) up to 9 years of follow up presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results of an analysis reporting report efficacy, safety, and quality of life (QOL) data from following clinical studies: NCT01745120, NCT02151526, NCT02906202, NCT03207009 and NCT02633943 presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 10 Dec 2023 According to bluebird bio media release, abstract containing data from this study presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top